Cappella, a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease,...
Cappella, a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, promoted their serial IVUS analysis and Sideguard® 3.25 device during the Joint Interventional Meeting (JIM) in Rome.
Gary S Mintz, MD of the Cardiovascular Research Foundation, New York, US, presented ‘Positive Vessel Remodelling Using Sideguard in Coronary Bifurcations’ during the New Technologies 1 Symposium. Dr Mintz highlighted that serial IVUS and OCT are ongoing in the Sideguard 3 study to confirm the initial findings of Sideguard 1 and assess stent strut coverage. The IVUS sub-study results from Sideguard 1 were published in the American Journal of Cardiology in October 2009.
The newest addition to the Sideguard portfolio, the Sideguard 3.25, was implanted successfully in a live case performed by Ralf Mueller, MD, Siegburg, Germany. According to Dr Mueller, “We implanted the Sideguard 3.25 stent together with a 3mm DES in a Medina 0,1,1 LAD/D1 stenosis. Positioning was easy and precise and IVUS demonstrated excellent scaffolding at the bifurcation. The use of the Sideguard device made this bifurcation intervention easy and predictable with an optimal acute result.”
Martin B Leon, MD, founder and director of Transcatheter Cardiovascular Therapeutics (TCT) and scientific advisory board member of Cappella, assisted with the case. Dr Leon expressed his satisfaction with the device: “It was the first time I used the 3.25 and I was very pleased with the outcome of the case.”